Pfizer, Inc. applies science and their global resources to bring therapies to people that extend and significantly improve their lives. In the drug discovery process, comprehensive chemical and biological entity registration systems play a pivotal role, underpinning and enabling companies to discover, characterize and develop novel new therapeutic entities. In this customer story, Steven Trudel, Chemistry Creation Center Lead in Molecule Design and Solutions Engineering for Pfizer, Inc. discusses how BIOVIA Biological and Chemical Registration enables Pfizer scientists to register small molecules and a variety of biological entities to enable Pfizer’s drug discovery efforts.
We now have the ability to register both chemicals and biologics in a common platform. We have been able to leverage our existing expertise and investment in Pipeline Pilot and now have the ability to add new entities easily.